Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 276850, 12 pages
http://dx.doi.org/10.1155/2015/276850
Review Article

Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases

1Department of Gastroenterology, Xiangya Hospital Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China
2GI Liver Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
3Department of Nutritional Science and Food Management, College of Health Science, Ewha Womans University, Seoul 150-750, Republic of Korea
4Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Davis Building 2094A, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA

Received 9 October 2014; Accepted 26 November 2014

Academic Editor: Caigan Du

Copyright © 2015 Ting Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Yang, T. W. H. Li, J. Peng et al., “A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression,” Gastroenterology, vol. 141, no. 1, pp. 378–388, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Yang, T. W. H. Li, K. S. Ko, M. Xia, and S. C. Lu, “Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes,” Hepatology, vol. 49, no. 3, pp. 860–870, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Grandori, S. M. Cowley, L. P. James, and R. N. Eisenman, “The Myc/Max/Mad network and the transcriptional control of cell behavior,” Annual Review of Cell and Developmental Biology, vol. 16, no. 1, pp. 653–699, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Wahlstrom and M. A. Henriksson, “Impact of MYC in regulation of tumor cell metabolism,” Biochimica et Biophysica Acta, 2014. View at Publisher · View at Google Scholar
  5. J. M. Link and P. J. Hurlin, “The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis,” Biochimica et Biophysica Acta-Gene Regulatory Mechanisms, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Voronov, Y. Carmi, and R. N. Apte, “The role IL-1 in tumor-mediated angiogenesis,” Frontiers in Physiology, no. 114, Article ID Article 114, pp. 1–8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Voronov, S. Dotan, Y. Krelin et al., “Unique versus redundant functions of IL-1α and IL-1β in the tumor microenvironment,” Frontiers in Immunology, vol. 4, article 177, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Szabo and T. Csak, “Inflammasomes in liver diseases,” Journal of Hepatology, vol. 57, no. 3, pp. 642–654, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Z. Mehal, “The inflammasome in liver injury and non-alcoholic fatty liver disease,” Digestive Diseases, vol. 32, no. 5, pp. 507–515, 2014. View at Publisher · View at Google Scholar
  10. K. Miura, Y. Kodama, S. Inokuchi et al., “Tolllike receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice,” Gastroenterology, vol. 139, no. 1, pp. 323–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. R. G. Gieling, K. Wallace, and Y.-P. Han, “Interleukin-1 participates in the progression from liver injury to fibrosis,” The American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 296, no. 6, pp. G1324–G1331, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Petrasek, S. Bala, T. Csak et al., “IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice,” The Journal of Clinical Investigation, vol. 122, no. 10, pp. 3476–3489, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J. P. Pradere, J. Kluwe, S. de Minicis et al., “Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice,” Hepatology, vol. 58, no. 4, pp. 1461–1473, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Wree, A. Eguchi, M. D. Mcgeough et al., “NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice,” Hepatology, vol. 59, no. 3, pp. 898–910, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. G. Borrello, D. Degl'Innocenti, and M. A. Pierotti, “Inflammation and cancer: the oncogene-driven connection,” Cancer Letters, vol. 267, no. 2, pp. 262–270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Shchors, E. Shchors, F. Rostker, E. R. Lawlor, L. Brown-Swigart, and G. I. Evan, “The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1β,” Genes and Development, vol. 20, no. 18, pp. 2527–2538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Voronov, D. S. Shouval, Y. Krelin et al., “IL-1 is required for tumor invasiveness and angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2645–2650, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. R. N. Apte and E. Voronov, “Is interleukin-1 a good or bad “guy” in tumor immunobiology and immunotherapy?” Immunological Reviews, vol. 222, no. 1, pp. 222–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Kang, P. G. Rychahou, T. A. Ishola, J. M. Mourot, B. M. Evers, and D. H. Chung, “N-Myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma,” Oncogene, vol. 27, no. 28, pp. 3999–4007, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. T. A. Baudino, C. McKay, H. Pendeville-Samain et al., “c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression,” Genes and Development, vol. 16, no. 19, pp. 2530–2543, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Burchill, J. Yang, K. B. Vang, and M. A. Farrar, “Interleukin-2 receptor signaling in regulatory T cell development and homeostasis,” Immunology Letters, vol. 114, no. 1, pp. 1–8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. C. Mingari, F. Gerosa, G. Carra et al., “Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells,” Nature, vol. 312, no. 5995, pp. 641–643, 1984. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Lenardo, F. K.-M. Chan, F. Hornung et al., “Mature T lymphocyte apoptosis—immune regulation in a dynamic and unpredictable antigenic environment,” Annual Review of Immunology, vol. 17, pp. 221–253, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Sikora, G. Dworacki, M. Trybus, H. Batura-Gabryel, and J. Zeromski, “Correlation between DNA content, expression of Ki-67 antigen of tumor cells and immunophenotype of lymphocytes from malignant pleural effusions,” Tumor Biology, vol. 19, no. 3, pp. 196–204, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Senba, M. Kurki, F. Arakawa et al., “Tumor growth suppression by a mouse/human ahimteric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model,” Anticancer Research, vol. 1A, no. 18, pp. 17–24, 1998. View at Google Scholar
  26. Y. Minami, Y. Nakagawa, A. Kawahara et al., “Protein tyrosine kinase Syk is associated with and activated by the IL-2 receptor: possible link with the c-myc induction pathway,” Immunity, vol. 2, no. 1, pp. 89–100, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Miyazaki, Z. J. Liu, A. Kawahara et al., “Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation,” Cell, vol. 81, no. 2, pp. 223–231, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. A.-B. Stittrich, C. Haftmann, E. Sgouroudis et al., “The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes,” Nature Immunology, vol. 11, no. 11, pp. 1057–1062, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Tinel, J. Elkahwaji, M. A. Robin et al., “Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes,” Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 2, pp. 649–655, 1999. View at Google Scholar · View at Scopus
  30. M. M. Fung, Y.-L. Chu, J. L. Fink, A. Wallace, and K. L. McGuire, “IL-2- and STAT5-regulated cytokine gene expression in cells expressing the Tax protein of HTLV-1,” Oncogene, vol. 24, no. 29, pp. 4624–4633, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. M. G. Neuman, J.-P. Benhamou, P. Marcellin et al., “Cytokine-chemokine and apoptotic signatures in patients with hepatitis C,” Translational Research, vol. 149, no. 3, pp. 126–136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Nelms, A. D. Keegan, J. Zamorano, J. J. Ryan, and W. E. Paul, “The IL-4 receptor: signaling mechanisms and biologic functions,” Annual Review of Immunology, vol. 17, pp. 701–738, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. I. G. Luzina, A. D. Keegan, N. M. Heller, G. A. W. Rook, T. Shea-Donohue, and S. P. Atamas, “Regulation of inflammation by interleukin-4: a review of “alternatives”,” Journal of Leukocyte Biology, vol. 92, no. 4, pp. 753–764, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. S. H. Cho, A. K. Ahn, P. Bhargava et al., “Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 38, pp. 15972–15977, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Soon, L. Flechner, J. S. Gutkind et al., “Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression,” Molecular and Cellular Biology, vol. 19, no. 5, pp. 3816–3828, 1999. View at Google Scholar · View at Scopus
  36. T. Sato, X. Liu, H. Basma et al., “IL-4 induces differentiation of human embryonic stem cells into fibrogenic fibroblast-like cells,” Journal of Allergy and Clinical Immunology, vol. 127, no. 6, pp. 1595.e9–1603.e9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Brock, M. Trenkmann, R. E. Gay, S. Gay, R. Speich, and L. C. Huber, “MicroRNA-18a enhances the interleukin-6-mediated production of the acute-phase proteins fibrinogen and haptoglobin in human hepatocytes,” The Journal of Biological Chemistry, vol. 286, no. 46, pp. 40142–40150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Trauner, P. Fickert, and R. E. Stauber, “Inflammation-induced cholestasis,” Journal of Gastroenterology and Hepatology (Australia), vol. 14, no. 10, pp. 946–959, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Picardi, U. V. Gentilucci, E. M. Zardi, D. D'Avola, A. Amoroso, and A. Afeltra, “The role of ribavirin in the combination therapy of hepatitis C virus infection,” Current Pharmaceutical Design, vol. 10, no. 17, pp. 2081–2092, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Xiang-Min, L. I. Da-Guang, C. Bo et al., “Alcoholic liver disease serum TGF-IL-6 and IL-8 levels and its clinical significance,” Chinese Journal of Laboratory Diagnosis, vol. 17, no. 7, pp. 1233–1234, 2013. View at Google Scholar
  41. H. Wehbe, R. Henson, F. Meng, J. Mize-Berge, and T. Patel, “Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression,” Cancer Research, vol. 66, no. 21, pp. 10517–10524, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Shi, P. Frost, B. Hoang, A. Benavides, J. Gera, and A. Lichtenstein, “IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the RNA-binding protein hnRNP A1,” The Journal of Biological Chemistry, vol. 286, no. 1, pp. 67–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Shamsasenjan, K.-I. Otsuyama, S. Abroun et al., “IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33(+) myeloma cells,” International Journal of Hematology, vol. 89, no. 3, pp. 310–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Ezure, T. Sakamoto, H. Tsuji et al., “The development and compensation of biliary cirrhosis in interleukin-6-deficient mice,” The American Journal of Pathology, vol. 156, no. 5, pp. 1627–1639, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Wang, F. Lafdil, X. Kong, and B. Gao, “Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target,” International Journal of Biological Sciences, vol. 7, no. 5, pp. 536–550, 2011. View at Google Scholar · View at Scopus
  46. J. Park, L. Tadlock, G. J. Gores, and T. Patel, “Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line,” Hepatology, vol. 30, no. 5, pp. 1128–1133, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. J. M. Saito and J. J. Maher, “Bile duct ligation in rats induces biliary expression of cytokine- induced neutrophil chemoattractant,” Gastroenterology, vol. 118, no. 6, pp. 1157–1168, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Syal, M. Fausther, and J. A. Dranoff, “Advances in cholangiocyte immunobiology,” The American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 303, no. 10, pp. G1077–G1086, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Seki and R. F. Schwabe, “Hepatic inflammation and fibrosis: functional links and key pathways,” Hepatology, 2014. View at Publisher · View at Google Scholar
  50. K. Bessho, R. Mourya, P. Shivakumar et al., “Gene expression signature for biliary atresia and a role for interleukin-8 in pathogenesis of experimental disease,” Hepatology, vol. 60, no. 1, pp. 211–223, 2014. View at Google Scholar
  51. R. S. Yahya, O. H. Ghanem, A. A. A. Foyouh, M. A. Atwa, and S. A. Enany, “Role of interleukin-8 and oxidative stress in patients with hepatocellular carcinoma,” Clinical Laboratory, vol. 59, no. 9-10, pp. 969–976, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. H. W. Zimmermann, S. Seidler, N. Gassler et al., “Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis,” PLoS ONE, vol. 6, no. 6, Article ID e21381, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. K. S. Ko, J. Peng, and H. Yang, “Animalmodels of cholangiocarcinoma,” Current Opinion in Gastroenterology, vol. 29, no. 3, pp. 312–318, 2013. View at Google Scholar
  54. K. Ninlawan, S. P. O'Hara, P. L. Splinter et al., “Opisthorchis viverrini excretory/secretory products induce toll-like receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyte,” Parasitology International, vol. 59, no. 4, pp. 616–621, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Gonzalez-Amaro, C. Garcia-Monzon, L. Garcia-Buey et al., “Induction of tumor necrosis factor α production by human hepatocytes in chronic viral hepatitis,” The Journal of Experimental Medicine, vol. 179, no. 3, pp. 841–848, 1994. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Fujimoto, M. Uemura, Y. Nakatani et al., “Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance,” Alcoholism: Clinical and Experimental Research, vol. 24, no. 4, supplement, pp. 48s–54s, 2000. View at Google Scholar · View at Scopus
  57. J. D. Gordan, J. A. Bertout, C.-J. Hu, J. A. Diehl, and M. C. Simon, “HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity,” Cancer Cell, vol. 11, no. 4, pp. 335–347, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. U. Florczyk, S. Czauderna, A. Stachurska et al., “Opposite effects of HIF-1α and HIF-2α on the regulation of IL-8 expression in endothelial cells,” Free Radical Biology and Medicine, vol. 51, no. 10, pp. 1882–1892, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Loboda, A. Stachurska, U. Florczyk et al., “HIF-1 induction attenuates Nrf2-dependent IL-8 expression in human endothelial cells,” Antioxidants & Redox Signaling, vol. 11, no. 7, pp. 1501–1517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. K. H. Yoo, Y. H. Sung, M. H. Yang et al., “Inactivation of Mxi1 induces Il-8 secretion activation in polycystic kidney,” Biochemical and Biophysical Research Communications, vol. 356, no. 1, pp. 85–90, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Zhang, P. Gao, R. Fukuda et al., “HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity,” Cancer Cell, vol. 11, no. 5, pp. 407–420, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Dominguez, R. Miquel, J. Colmenero et al., “Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis,” Gastroenterology, vol. 136, no. 5, pp. 1639–1650, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. A. de la Coste, A. Mignon, M. Fabre et al., “Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice,” Cancer Research, vol. 59, no. 19, pp. 5017–5022, 1999. View at Google Scholar · View at Scopus
  64. P. J. Murray, “Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response,” Current Opinion in Pharmacology, vol. 6, no. 4, pp. 379–386, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Yu, M. Dews, A. Park, J. W. Tobias, and A. Thomas-Tikhonenko, “Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies,” Cancer Research, vol. 65, no. 12, pp. 5454–5461, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Robert, J. R. Mills, A. Agenor et al., “Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival,” Cancer Research, vol. 72, no. 3, pp. 747–756, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Rai, A. Plagov, X. Lan et al., “mTOR plays a critical role in p53-induced oxidative kidney cell injury in HIVAN,” The American Journal of Physiology: Renal Physiology, vol. 305, no. 3, pp. F343–F354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. Z. Lai, S. Kalkunte, and S. Sharma, “A critical role of interleukin-10 in modulating hypoxia-induced preeclampsia-like disease in mice,” Hypertension, vol. 57, no. 3, pp. 505–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. J. A. Fielhaber, Y.-S. Han, J. Tan et al., “Inactivation of mammalian target of rapamycin increases STAT1 nuclear content and transcriptional activity in α4- and protein phosphatase 2A-dependent fashion,” The Journal of Biological Chemistry, vol. 284, no. 36, pp. 24341–24353, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Wang, Y. Zhao, Y. Liu et al., “IFN-γ and TNF-α synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFκB signaling,” Stem Cells, vol. 31, no. 7, pp. 1383–1395, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. V. K. W. Wong, M. M. Zhang, H. Zhou et al., “Saikosaponin-d enhances the anticancer potency of TNF-α via overcoming its undesirable response of activating NF-kappa B signalling in cancer cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 745295, 14 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Fernandez, M. C. Marin, T. McDonnell, and H. N. Ananthaswamy, “Differential sensitivity of normal and Ha-ras-transformed C3H mouse embryo fibroblasts to tumor necrosis factor: induction of bcl-2, c-myc, and manganese superoxide dismutase in resistant cells,” Oncogene, vol. 9, no. 7, pp. 2009–2017, 1994. View at Google Scholar · View at Scopus
  73. A. Tobler, D. Johnston, and H. P. Koeffler, “Recombinant human tumor necrosis factor(α) regulates c-myc expression in HL-60 cells at the level of transcription,” Blood, vol. 70, no. 1, pp. 200–205, 1987. View at Google Scholar · View at Scopus
  74. S. Dooley and P. Ten Dijke, “TGF-β in progression of liver disease,” Cell and Tissue Research, vol. 347, no. 1, pp. 245–256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Turcatel, N. Rubin, A. El-Hashash, and D. Warburton, “Mir-99a and mir-99b modulate TGF-β induced epithelial to mesenchymal plasticity in normal murine mammary gland cells,” PLoS ONE, vol. 7, no. 1, Article ID e31032, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Maggio-Price, P. Treuting, H. Bielefeldt-Ohmann et al., “Bacterial infection of Smad3/Rag2 double-null mice with transforming growth factor-β dysregulation as a model for studying inflammation-associated colon cancer,” The American Journal of Pathology, vol. 174, no. 1, pp. 317–329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Yoshida and K. Matsuzaki, “Differential regulation of TGF-β/Smad signaling in hepatic stellate cells between acute and chronic liver injuries,” Frontiers in Physiology, vol. 3, article 53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. R. J. Grumont, A. Strasser, and S. Gerondakis, “B Cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-κB regulated c-myc transcription,” Molecular Cell, vol. 10, no. 6, pp. 1283–1294, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. F. Siebelt, I. Berberich, G. Shu, E. Serfling, and E. A. Clark, “Role for CD40-mediated activation of c-Rel and maintenance of c-myc RNA levels in mitigating anti-IgM-induced growth arrest,” Cellular Immunology, vol. 181, no. 1, pp. 13–22, 1997. View at Publisher · View at Google Scholar · View at Scopus
  80. Z. Wang, J. P. Xu, Y. C. Zheng et al., “Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats,” Hepatobiliary and Pancreatic Diseases International, vol. 10, no. 1, pp. 64–71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Shen, E. S. H. Chu, G. Zhao et al., “PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice,” British Journal of Cancer, vol. 106, no. 9, pp. 1486–1494, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Matsusue, M. Haluzik, G. Lambert et al., “Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 737–747, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. B. Zarnegar, J. Q. He, G. Oganesyan, A. Hoffmann, D. Baltimore, and G. Cheng, “Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-κB activation pathways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 21, pp. 8108–8113, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. J. J. Schlezinger, B. A. Jensen, K. K. Mann, H. Y. Ryu, and D. H. Sherr, “Peroxisome proliferator-activated receptor γ-mediated NF-kappaB activation and apoptosis in pre-B cells,” Journal of Immunology, vol. 169, no. 12, pp. 6831–6841, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. Z. You, L. V. Madrid, D. Saims, J. Sedivy, and C.-Y. Wang, “c-Myc sensitizes cells to tumor necrosis factor-mediated apoptosis by inhibiting nuclear factor κB transactivation,” Journal of Biological Chemistry, vol. 277, no. 39, pp. 36671–36677, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. F. A. L. A. Rosa, J. W. Pierce, and G. E. Sonenshein, “Differential regulation of the c-myc oncogene promoter by the NF-κB Rel family of transcription factors,” Molecular and Cellular Biology, vol. 14, no. 2, pp. 1039–1044, 1994. View at Google Scholar · View at Scopus
  87. R. Visconti, J. Cerutti, S. Battista et al., “Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF κB p65 protein expression,” Oncogene, vol. 15, no. 16, pp. 1987–1994, 1997. View at Publisher · View at Google Scholar · View at Scopus
  88. D. W. Kim, L. Gazourian, S. A. Quadri, D. H. Sherr, and G. E. Sonenshein, “The RelA NF-κB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells,” Oncogene, vol. 19, no. 48, pp. 5498–5506, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Beer, A. Zetterberg, R. A. Ihrie et al., “Developmental context determines latency of MYC-induced tumorigenesis,” PLoS Biology, vol. 2, no. 11, pp. 1785–1798, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Amicone, O. Terradillos, L. Calvo et al., “Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-β signalling in the control of liver homeostasis and transformation,” Oncogene, vol. 21, no. 9, pp. 1335–1345, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Kim, Q. Li, C. V. Dang, and L. A. Lee, “Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 21, pp. 11198–11202, 2000. View at Publisher · View at Google Scholar · View at Scopus
  92. E. Baena, A. Gandarillas, M. Vallespinós et al., “c-Myc regulates cell size and ploidy but is not essential for postnatal proliferation in liver,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 20, pp. 7286–7291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. H. P. Glauert, A. Eyigor, J. C. Tharappel, S. Cooper, E. Y. Lee, and B. T. Spear, “Inhibition of hepatocarcinogenesis by the deletion of the p50 subunit of NF-κB in mice administered the peroxisome proliferator Wy-14,643,” Toxicological Sciences, vol. 90, no. 2, pp. 331–336, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. H. Ishikawa, E. Claudio, D. Dambach, C. Raventós-Suárez, C. Ryan, and R. Bravo, “Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-κB1) but expressing p50,” The Journal of Experimental Medicine, vol. 187, no. 7, pp. 985–996, 1998. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Bosschaerts, Y. Morias, B. Stijlemans et al., “IL-10 limits production of pathogenic TNF by M1 myeloid cells through induction of nuclear NF-κB p50 member in Trypanosoma congolense infection-resistant C57BL/6 mice,” European Journal of Immunology, vol. 41, no. 11, pp. 3270–3280, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. N. R. Chapman, G. A. Webster, P. J. Gillespie, B. J. Wilson, D. H. Crouch, and N. D. Perkins, “A novel form of the RelA nuclear factor κB subunit is induced by and forms a complex with the proto-oncogene c-Myc,” Biochemical Journal, vol. 366, no. 2, pp. 459–469, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Klefstrom, E. Arighi, T. Littlewood et al., “Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-κB activation,” The EMBO Journal, vol. 16, no. 24, pp. 7382–7392, 1997. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Klefstrom, I. Västrik, E. Saksela, J. Valle, M. Eilers, and K. Alitalo, “c-Myc induces cellular susceptibility to the cytotoxic action of TNF-α,” The EMBO Journal, vol. 13, no. 22, pp. 5442–5450, 1994. View at Google Scholar · View at Scopus
  99. T. Hsu, T. Moroy, J. Etiemble et al., “Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma,” Cell, vol. 55, no. 4, pp. 627–635, 1988. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Transy, G. Fourel, W. S. Robinson, P. Tiollais, P. L. Marion, and M.-A. Buendia, “Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 9, pp. 3874–3878, 1992. View at Publisher · View at Google Scholar · View at Scopus
  101. H. Yang, T. W. H. Li, Y. Zhou et al., “Activation of a novel c-Myc-miR27-Prohibitin 1 circuitry in cholestatic liver injury inhibits GSH synthesis in mice,” Antioxidants & Redox Signaling, vol. 22, no. 3, pp. 259–274, 2015. View at Publisher · View at Google Scholar
  102. K.-L. Chan, X.-Y. Guan, and I. O.-L. Ng, “High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma,” Human Pathology, vol. 35, no. 11, pp. 1324–1331, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Asim, R. Chaturvedi, S. Hoge et al., “Helicobacter pylori induces ERK-dependent formation of a phospho-c-Fos·c-Jun activator protein-1 complex that causes apoptosis in macrophages,” The Journal of Biological Chemistry, vol. 285, no. 26, pp. 20343–20357, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. L. Min, Y. Ji, L. Bakiri et al., “Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin,” Nature Cell Biology, vol. 14, no. 11, pp. 1203–1211, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. N. Kalra and V. Kumar, “c-Fos is a mediator of the c-Myc-induced apoptotic signaling in serum-deprived hepatoma cells via the p38 mitogen-activated protein kinase pathway,” The Journal of Biological Chemistry, vol. 279, no. 24, pp. 25313–25319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Behrens, M. Sibilia, J.-P. David et al., “Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver,” EMBO Journal, vol. 21, no. 7, pp. 1782–1790, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. E. Stepniak, R. Ricci, R. Eferl et al., “c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity,” Genes and Development, vol. 20, no. 16, pp. 2306–2314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. L. Hui, K. Zatloukal, H. Scheuch, E. Stepniak, and E. F. Wagner, “Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation,” The Journal of Clinical Investigation, vol. 118, no. 12, pp. 3943–3953, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. T. Sakurai, S. Maeda, L. Chang, and M. Karin, “Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 28, pp. 10544–10551, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. J. Pihlajamäki, T. Kuulasmaa, D. Kaminska et al., “Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans,” Journal of Hepatology, vol. 56, no. 3, pp. 663–670, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Seidler, H. W. Zimmermann, R. Weiskirchen, C. Trautwein, and F. Tacke, “Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes,” BMC Gastroenterology, vol. 12, article 38, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. R. Bahirwani and K. R. Reddy, “Drug-induced liver injury due to cancer chemotherapeutic agents,” Seminars in Liver Disease, vol. 34, no. 2, pp. 162–171, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. B. Gao, “Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease,” Journal of Gastroenterology and Hepatology, vol. 27, no. 2, pp. 89–93, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Bonacini, M. Ghabril, and H. L. Bonkovsky, “Hepatotoxicity of anti-TNF agents,” Digestive Diseases and Sciences, vol. 59, no. 5, pp. 1070–1071, 2014. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Dooley and P. T. Dijke, “TGF-β in progression of liver disease,” Cell and Tissue Research, vol. 347, no. 1, pp. 245–256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. P. Liu, E. Kimmoun, A. Legrand et al., “Activation of NF-kappaB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas,” Journal of Hepatology, vol. 37, no. 1, pp. 63–71, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. C. Dorn, J. C. Engelmann, M. Saugspier et al., “Increased expression of c-Jun in nonalcoholic fatty liver disease,” Laboratory Investigation, vol. 94, no. 4, pp. 394–408, 2014. View at Publisher · View at Google Scholar · View at Scopus
  118. S. C. Hasenfuss, L. Bakiri, M. K. Thomsen, E. G. Williams, J. Auwerx, and E. F. Wagner, “Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers,” Cell Metabolism, vol. 19, no. 1, pp. 84–95, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. Y. Liu, C. Lu, Q. Shen, D. Munoz-Medellin, H. Kim, and P. H. Brown, “AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity,” Oncogene, vol. 23, no. 50, pp. 8238–8246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. Y. Tachibana, Y. Nakamoto, N. Mukaida, and S. Kaneko, “Intrahepatic interleukin-8 production during disease progression of chronic hepatitis C,” Cancer Letters, vol. 251, no. 1, pp. 36–42, 2007. View at Publisher · View at Google Scholar · View at Scopus
  121. J.-F. A. Tsai, J.-E. Jeng, L.-Y. Chuang, W.-Y. U. Chang, and J.-H. Tsai, “Urinary transforming growth factor β1 levels in hepatitis c virus-related chronic liver disease: correlation between high levels and severity of disease,” Hepatology, vol. 25, no. 5, pp. 1141–1146, 1997. View at Publisher · View at Google Scholar · View at Scopus
  122. M. A. Ali, B. A. Koura, N. el-Mashad, and M. H. E. Zaghloul, “The Bcl-2 and TGF-beta1 levels in patients with chronic hepatitis C, liver cirrhosis and hepatocellular carcinoma,” The Egyptian Journal of Immunology, vol. 11, no. 1, pp. 83–90, 2004. View at Google Scholar · View at Scopus
  123. M. Reiser, C. G. Marousis, D. R. Nelson et al., “Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection,” Journal of Hepatology, vol. 26, no. 3, pp. 471–478, 1997. View at Publisher · View at Google Scholar · View at Scopus
  124. D. Xiaoyan, C. Jun, and D. Hong, “Hepatitis b and hepatitis c virus (HCV) for the c-jun gene of regulation,” World Journal of Gastroenterology, vol. 12, no. 4, pp. 935–937, 2004. View at Google Scholar
  125. F. Giammarco, “Molecular mechanisms of cholangiocarcinoma,” World Journal of Gastrointestinal Pathophysiology, vol. 1, no. 1, pp. 12–22, 2010. View at Google Scholar
  126. L. L. Giong, L. Jia, and K. Zengji, “Cytokines and alcoholic liver disease,” Chinese Bulletin of Life Sciences, vol. 22, no. 12, pp. 1241–1246, 2010. View at Google Scholar
  127. F. T. Crews, R. Bechara, L. A. Brown et al., “Cytokines and alcohol,” Alcoholism: Clinical and Experimental Research, vol. 30, no. 4, pp. 720–730, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Akiba, H. Yano, and S. Ogasawara, “Expression and function of interleukin-8 in human hepatocellular carcinoma,” International Journal of Oncology, vol. 18, no. 2, pp. 257–264, 2001. View at Google Scholar · View at Scopus
  129. P. Liu, J. F. Flejou, G. Feldmann, and D. Bernuau, “Activation of ras oncogene in livers with cirrhosis,” Journal of Hepatology, vol. 21, no. 6, pp. 1103–1108, 1994. View at Publisher · View at Google Scholar · View at Scopus
  130. M. S. Hayden, A. P. West, and S. Ghosh, “NF-κB and the immune response,” Oncogene, vol. 25, no. 51, pp. 6758–6780, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. M. M. Kemeny, G. I. Botchkina, M. Ochani, M. Bianchi, C. Urmacher, and K. J. Tracey, “The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 8, pp. 4561–4566, 1998. View at Publisher · View at Google Scholar · View at Scopus
  132. L. C. Miller, A. Sharma, A. F. McKusick, J. P. Tassoni, C. A. Dinarello, and M. M. Kaplan, “Synthesis of interleukin-1β in primary biliary cirrhosis: relationship to treatment with methotrexate or colchicine and disease progression,” Hepatology, vol. 22, no. 2, pp. 518–524, 1995. View at Publisher · View at Google Scholar · View at Scopus
  133. K. Wakabayashi, Z. X. Lian, Y. Moritoki et al., “IL-2 receptor α-/- mice and the development of primary biliary cirrhosis,” Hepatology, vol. 44, no. 5, pp. 1240–1249, 2006. View at Publisher · View at Google Scholar · View at Scopus
  134. C. Homann, T. L. Benfield, N. Albertgrauda, and P. Garred, “Neopterin and interleukin-8—prognosis in alcohol-induced cirrhosis,” Liver International, vol. 20, no. 6, pp. 442–449, 2000. View at Publisher · View at Google Scholar · View at Scopus
  135. S. Kitaoka, G. Shiota, and H. Kawasaki, “Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C,” Hepato-Gastroenterology, vol. 50, no. 53, pp. 1569–1574, 2003. View at Google Scholar · View at Scopus
  136. Y. Ding, L. Zhao, H. Mei, Z.-H. Huang, and S.-L. Zhang, “Alterations of biliary biochemical constituents and cytokines in infantile hepatitis syndrome,” World Journal of Gastroenterology, vol. 12, no. 43, pp. 7038–7041, 2006. View at Google Scholar · View at Scopus
  137. K. Kovalovich, W. Li, R. DeAngelis, L. E. Greenbaum, G. Ciliberto, and R. Taub, “Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL,” The Journal of Biological Chemistry, vol. 276, no. 28, pp. 26605–26613, 2001. View at Publisher · View at Google Scholar · View at Scopus
  138. A. Kasprzak, M. Zabel, W. Biczysko et al., “Expression of cytokines (TNF-α, IL-1α, and IL-2) in chronic hepatitis c: comparative hybridocytochemical and immunocytochemical study in children and adult patients,” Journal of Histochemistry and Cytochemistry, vol. 52, no. 1, pp. 29–38, 2004. View at Publisher · View at Google Scholar · View at Scopus
  139. K. Migita, S. Miyazoe, Y. Maeda et al., “Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection—association between TGF-β1 polymorphisms and hepatocellular carcinoma,” Journal of Hepatology, vol. 42, no. 4, pp. 505–510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  140. P. Utaisincharoen, S. Ubol, N. Tangthawornchaikul, P. Chaisuriya, and S. Sirisinha, “Binding of tumour necrosis factor-alpha (TNF-α) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines,” Clinical and Experimental Immunology, vol. 116, no. 1, pp. 41–47, 1999. View at Publisher · View at Google Scholar · View at Scopus